Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Fineline Cube Jan 15, 2026
Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Fineline Cube Jan 15, 2026
Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Deals

Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech

Fineline Cube Apr 16, 2025

Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp...

Company Drug Policy / Regulatory

US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security

Fineline Cube Apr 16, 2025

The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the...

Company

Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech

Fineline Cube Apr 16, 2025

US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...

Company Drug

BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study

Fineline Cube Apr 15, 2025

US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...

Company Drug

Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males

Fineline Cube Apr 15, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has initiated a Phase III...

Company Drug

Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer’s Disease

Fineline Cube Apr 15, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors

Fineline Cube Apr 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced clearance from the National Medical...

Company Drug

Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case

Fineline Cube Apr 15, 2025

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...

Company Drug

Roche’s Columvi Approved by EC for Relapsed DLBCL Treatment in Europe

Fineline Cube Apr 15, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-1819 in Allergic Rhinitis Study

Fineline Cube Apr 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval...

Company Drug

CSPC Pharmaceutical Gains FDA Approval for SYS6041 ADC in Advanced Solid Tumors

Fineline Cube Apr 15, 2025

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...

Company Deals

Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases

Fineline Cube Apr 15, 2025

Germany’s Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc....

Company Medical Device

Peijia Medical’s TaurusTrio TAV System Accepted for NMPA Review in China

Fineline Cube Apr 15, 2025

China-based Peijia Medical Ltd (HKG: 9996) has announced that the National Medical Products Administration (NMPA)...

Company Drug

HighTide Therapeutics’ HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment

Fineline Cube Apr 15, 2025

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical...

Company Drug

Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259

Fineline Cube Apr 15, 2025

China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance...

Company Deals

Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production

Fineline Cube Apr 15, 2025

Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured...

Company Deals

Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters

Fineline Cube Apr 15, 2025

UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503)...

Company Drug

MSD’s Gardasil 9 Approved in China for Males Aged 16 to 26

Fineline Cube Apr 14, 2025

US pharmaceutical major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced marketing approval from...

Policy / Regulatory

NHC Urges Hospitals to Establish Healthy Weight Management Clinics by June

Fineline Cube Apr 14, 2025

The National Health Commission (NHC) has issued a notification encouraging eligible Class 3 general hospitals,...

Company Deals

Mabwell and DP Technology Collaborate to Build Biopharma AI Platform for Drug Development

Fineline Cube Apr 14, 2025

Chinese companies Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) and DP Technology have entered into...

Posts pagination

1 … 121 122 123 … 609

Recent updates

  • Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
  • Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
  • QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
  • Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific
  • WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Company Digital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.